Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects

Antiviral Research

Volumn 134, Issue , 2016, Pages 144-152

  Yates, Phillip J ^a   Raimonde, Dawn S ^b   Zhao, Henry H ^b,c   Man, Choy Y ^b   Steel, Helen M ^a   Mehta, Nalini ^a   Peppercorn, Amanda F ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Bristol Myers Squib   (United States)

Author keywords

Antiviral susceptibility; Influenza; Intravenous zanamivir

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; ZANAMIVIR; HEMAGGLUTININ; SIALIDASE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; GENOTYPE; HOSPITAL PATIENT; HUMAN; IC50; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS CULTURE; VIRUS GENE; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS VIRULENCE; ANTIVIRAL RESISTANCE; CLASSIFICATION; CLINICAL TRIAL; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HOSPITALIZATION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MULTICENTER STUDY; VIROLOGY;

ADMINISTRATION, INTRAVENOUS; ADULT; DRUG RESISTANCE, VIRAL; GENOTYPE; HEMAGGLUTININS; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; NEURAMINIDASE; PHENOTYPE; SEQUENCE ANALYSIS, DNA; ZANAMIVIR;

EID: 84987920191     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.08.023     Document Type: Article

References (32)

1. Aoki, F.Y., Boivin, G., Roberts, N., Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 12 (2007), 603–616.
2. Blick, T.J., Sahasrabudhe, A., McDonald, M., Owens, I.J., Morley, P.J., Fenton, R.J., McKimm-Breschkin, J.L., The interaction of neuraminidase and hemmagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 246 (1998), 95–103.
3. Chan, P.K.S., Lee, N., Joynt, G.M., Choi, K.W., Cheung, J.L.K., Yeung, A.C.M., Lam, P., Wong, R., Leung, B.-W., So, H.-Y., Lam, W.-Y., Hui, D.C.S., Clinical and virological course of infection with haemagglutinin D222G mutant strain of 2009 pandemic influenza A (H1N1) virus. J. Clin. Virol. 50 (2011), 320–324.
4. Dong, G., Peng, C., Luo, J., Wang, C., Han, L., Wu, B., Ji, G., He, H., Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One, 10(3), 2015, e0119115, 10.1371/journal.pone.0119115. eCollection 2015.
5. Ghedin, E., Laplante, J., DePasse, J., Wentworth, D.E., Santos, R.P., Lepow, M.L., Porter, J., Stellrecht, K., Lin, X., Operario, D., Griesemer, S., Fitch, A., Halpin, R.A., Stockwell, T.B., Spiro, D.J., Holmes, E.C., St. George, K., Deep sequencing reveals mixed infection with 2009 pandemic influenza a (H1N1) virus strains and the emergence of oseltamivir resistance. J. Infect. Dis. 203 (2011), 168–174.
6. Gubareva, L.V., Matrosovich, M.N., Brenner, M.K., Bethell, R.C., Webster, R.G., Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 (1998), 1257–1262.
7. Hurt, A.C., Holien, J.K., Parker, M., Kelso, A., Barr, I.G., Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 83:20 (2009), 10366–10373.
8. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG. 2011. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill.; 16(23). pii: 19884. Erratum in: Euro Surveill.; 16(27) pii: 19909.
9. Jackson, D., Barclay, W., Zurcher, T., Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55 (2005), 162–169.
10. Kilander, A., Rykkvin, R., Dudman, S.G., Hungnes, O., Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill., 15(9), 2010 pii: 19498. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19498.
11. Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9 (2012), 357–359.
12. Leang, S.-K., Deng, Y.-M., Shaw, R., Caldwell, N., Iannello, P., Komadina, N., Buchy, P., Chittaganpitch, M., Dwyer, D.E., Fagan, P., Gourinat, A.-C., Hammill, F., Horwood, P.F., Huang, Q.S., Ip, P.K., Jennings, L., Kesson, A., Kok, T., Kool, J.L., Levy, A., Lin, C., Lindsay, K., Osman, O., Papadakis, G., Rahnamal, F., Rawlinson, W., Redden, C., Ridgway, J., Sam, I.-C., Svobodova, S., Tandoc, A., Wickramasinghe, G., Williamson, J., Wilson, N., Yusof, M.A., Kelso, A., Barr, I.G., Hurt, A.C., Influenza antiviral resistance in the Asia-Pacific region during 2011. Antivir. Res. 97 (2013), 206–210.
13. L'Huillier, A.G., Abed, Y., Petty, T.J., Cordey, S., Thomas, Y., Bouhy, X., Schibler, M., Simon, A., Chalandon, Y., van Delden, C., Zdobnov, E., Boquete-Suter, P., Boivin, G., Kaiser, L., E119D neuraminidase mutation conferring Pan-Resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J. Infect. Dis. 212 (2015), 1726–1734.
14. Li, T.C.M., Chan, M.C.W., Lee, N., Clinical implications of antiviral resistance in influenza. Viruses 7 (2015), 4929–4944, 10.3390/v7092850.
15. Marty, F.M., Man, C.Y., van der Horst, C., Francois, B., Garot, D., Máňez, R., Thamlikitkul, V., Lorente, J.A., Álvarez-Lerma, F., Brealey, D., Zhao, H.H., Weller, S., Yates, P.J., Peppercorn, A.F., Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J. Infect. Dis. 209:4 (2013), 542–550 15.
16. McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., Zambon, M., Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:7 (2003), 2264–2272.
17. Monto, A.S., McKimm-Breschkin, J.L., Macken, C., Hampson, A.W., Hay, A., Klimov, A., Tashiro, M., Webster, R.G., Aymard, M., Hayden, F.G., Zambon, M., Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 Years of their use. Antimicrob. Agents Chemother. 50:7 (2006), 2395–2402.
18. Nguyen, H.T., Fry, A.M., Loveless, P.A., Klimov, A.I., Gubareva, L.V., Recovery of a multi-drug resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Inf. Dis. 51 (2010), 983–984.
19. Nguyen, H.T., Fry, A.M., Gubareva, L.V., Neuraminidase Inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17 (2012), 159–173.
20. Okomo-Adhiambo, M., Nguyen, H.T., Sleeman, K., Sheu, T.G., Deyde, V.M., Garten, R.J., Xu, X., Shaw, M.W., Klimov, A.I., Gubareva, L.V., Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 85:2 (2009), 381–388.
21. Okomo-Adhiambo, M., Demmler-Harrison, G.J., Deyde, V.M., Sheu, T.G., Xu, X., Klimov, A.I., Gubareva, L.V., Detection of E119V and E119I mutations in influenza a (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:5 (2010), 1834–1841.
22. Peppercorn, A., Man, C.Y., Zhao, H.H., Weller, S., Yates, P.J., Raimonde, D., Lou, Y., Steel, H., Clinical outcomes, viral load and pharmacokinetics following treatment with IV zanamivir in hospitalized adults with influenza: results from a Phase 2 open-label, multicenter, single arm study initiated during the influenza A H1N1 pandemic. OPTIONS for the Control of Influenza Congress, Cape Town, SA, 2013.
23. Rousset, D., Goff, J.L., Abou-Jaoude, G.A., Scemla, A., Ribaud, P., Mercier-Delaurue, S., Caro, V., Enouf, V., Simon, F., Molina, J.M., van der Werf, S., Emergence of successive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivir resistance and reduced susceptibility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors. OPTIONS for the Control of Influenza Congress, Hong Kong, Abstract, P-198, 2010.
24. Sheu, T.G., Deyde, V.M., Garten, R.J., Klimov, A.I., Gubareva, L.V., Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antivir. Res. 85 (2010), 354–360.
25. Tamura, D., DeBiasi, R.L., Okomo-Adhiambo, M., Mishin, V.P., Campbell, A.P., Loechelt, B., Wiedermann, B.L., Fry, A.M., Gubareva, L.V., Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J. Infect. Dis. 212 (2015), 1209–1213.
26. Tisdale, M., Influenza M2 ion-channel and neuraminidase inhibitors. Mayers, D.L., Lerner, S.A., Ouellette, M., Sobel, J.D., (eds.) Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, vol. 1, 2009, 421–447, 10.1007/978-1-59745-180-2_31.
27. Valinotto, L.E., Diez, R.A., Barrero, P.R., Farias, J.A., Lopez, E.L., Mistchenko, A.S., Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. Antivir. Ther., 15, 2010, 923.
28. van der Vries, E., Stelma, F.F., Boucher, C.A., Emergence of a multi-drug resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:14 (2010), 1381–1382.
29. World Health Organisation, Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. 2011 Available at: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf.
30. World Health Organisation, Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87 (2012), 369–374.
31. Yates, P.J., Mehta, N., Horton, J., Tisdale, M., Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob. Agents Chemother., 57(4), 2013, 1677.
32. Zurcher, T., Yates, P.J., Daly, J., Sahasrabudhe, A., Walters, M., Dash, L., Tisdale, M., McKimm-Breschkin, J.L., Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J. Antimicrob. Chemother. 58 (2006), 723–732.